Malutiple-institutional observational surveillance of Pembrolizumab as a first line treatment for non-small cell lung cancer

Malutiple-institutional observational surveillance of Pembrolizumab as a first line treatment for non-small cell lung cancer - Observational surveillance of Pembrolizumab as a 1st line treatment for NSCLC

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000032470

Enrollment

150

Registered

2018-05-04

Start date

2018-05-04

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

non small cell lung cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Patients with a definite diagnosis of NSCLC based on histology or cytology. 2) Patients unsuitable for curative radiation therapy who have a clinical diagnosis of either recurrent disease or stage IV NSCLC. 3) Patients who receive at least one dose of pembrolizumab.

Exclusion criteria

Exclusion criteria: 1)Patients who have previously received pembrolizumab in a clinical trial will be excluded 2)Pretreated chemotherapy

Design outcomes

Primary

Measure	Time frame
To investigate whether obsertive analysis of nivolumab therapy in the real clinical setting reproduces the RR shown by primary analysis of the KeyNote-024 trial.	—

Countries

Japan

Contacts

Public ContactFujimoto Daichi

Kobe City Medical Center General Hospital Respiratory Medicine

daichianzen@yahoo.co.jp078-302-4321

Outcome results